CytomX Therapeutics Inc.
CTMX | NASDAQ
$2.76
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$2.75
-$0.01 (-0.36%)
Pre-market:
Sep 22, 2026, 5:01 AM ET
Market Data
Market Cap $600.86M
Enterprise Value $276.28M
Beta 2.14
Average Volume 3.78M
Shares Outstanding (Diluted) 218.94M
Shares Change YoY 69.62%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US23284F1057
Price Performance
Price Change 1M -17.1%
Price Change 3M -12.4%
Price Change 6M -34.6%
Price Change YTD -35.1%
Price Change 1Y 34.0%
Price Change 3Y 115.6%
Price Change 5Y -47.5%
1M CAGR (ann.) -18.1%
1Y CAGR (ann.) 43.0%
5Y CAGR (ann.) -11.6%
All-Time CAGR -13.1%
Valuation
PE Ratio -6.13
Forward PE N/A
PEG Ratio 0.04
Forward PEG -0.31
PS Ratio 32.83
Forward PS 19.80
PB Ratio 1.99
P/FCF Ratio -5.56
P/Adj. FCF Ratio -4.89
P/OCF Ratio -7.26
EV/Sales 15.10
EV/EBIT -3.48
EV/EBITDA -3.53
EV/FCF -2.56
Earnings Yield -16.3%
FCF Yield -18.0%
Adj. FCF Yield -20.4%
Financial Health
Net Cash $324.58M
Total Debt $5.7M
Cash & Short-Term Investments $330.28M
Total Assets $381.23M
Current Ratio 9.36
Quick Ratio 9.36
Debt / Equity Ratio 0.02
Debt / EBITDA -0.07
Debt / FCF -0.05
OCF / Debt -18.93
Interest Coverage 0.00
Altman Z-Score 2.21
Piotroski F-Score 1
Margins & Profitability
Gross Profit Margin 98.6%
Operating Profit Margin -476.2%
EBITDA Margin -427.4%
Net Profit Margin -435.2%
FCF Margin -590.3%
Adj. FCF Margin -671.4%
SBC / Revenue 55.4%
SBC Impact (per share) -13.8%
Returns
Return on Assets -20.9%
Return on Equity -38.5%
Return on Invested Capital -25.4%
Return on Capital Employed -25.5%
Return on Tangible Assets -21.0%
Historical Growth (CAGR)
Revenue CAGR 3Y -38.7%
Revenue CAGR 5Y -22.7%
Revenue CAGR 10Y 7.1%
EPS CAGR 3Y -327.8%
EPS CAGR 5Y 86.0%
EPS CAGR 10Y 22.8%
FCF CAGR 3Y -12.0%
FCF CAGR 5Y 3.8%
FCF CAGR 10Y -26.3%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 21
EPS Growth Next 3Y 3.0%
Revenue Growth Next 3Y 43.8%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $8.50
Price Target Upside 208.0%
Cash Flow
Operating Cash Flow $-107.96M
Free Cash Flow $-108.03M
Adj. Free Cash Flow $-122.88M
FCF Per Share -$0.38
OCF Per Share -$0.38
OCF/S Ratio -450.3%
Income Statement
Revenue $18.3M
Gross Profit $18.05M
Operating Income $-87.15M
EBITDA $-78.23M
Net Income $-79.65M
EPS (Diluted) -$0.45
Revenue / Employee $265.25K
Profit / Employee $-1.15M
Employees 69
Add to Watchlist
Select watchlists to add or remove CTMX